Introduction {#Sec1}
============

Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder involving the colonic mucosa. It is characterized by periods of active symptomatic disease interspersed with periods of clinical remission \[[@CR1]\]. A 2012 systematic review indicated worldwide UC prevalence rates of up to 249 per 100,000 persons in North America and 505 per 100,000 persons in Europe; the highest reported annual incidence rates of UC were 19.2 per 100,000 person-years in North America and 24.3 per 100,000 person-years in Europe \[[@CR2]\]. The highest incidence appears to occur during the age range of 20--30 years, although there is some evidence for a second peak in incidence later in life \[[@CR2]\].

Endoscopic examination of the colon in patients with UC reveals a number of characteristic changes seen in the mucosa, including loss of vascular pattern, erythema, granularity, friability, erosions, and ulceration \[[@CR1], [@CR3]\]. Mucosal healing, which has been defined as complete resolution of the visible alterations or lesions, regardless of their baseline nature or severity, is emerging as an important goal in the management of inflammatory bowel diseases such as UC; increasing evidence indicates that mucosal healing is associated with reductions in the number of disease flares, hospitalizations, and the need for colectomy in patients with UC \[[@CR4]\].

Classic symptoms of UC include rectal bleeding, diarrhea, urgency, tenesmus, and abdominal pain \[[@CR1]\], and these can impose a substantial burden on patients. Patients with UC report problems in a number of aspects of their daily lives, including withdrawal from social situations, employment disruption, increased anxiety, and decrease in health-related quality of life \[[@CR5]--[@CR7]\].

Current US \[[@CR8]\] and European \[[@CR9]\] guidelines recommend treatment with 5-aminosalicylates (5-ASAs) as first-line therapy for the induction of remission in patients with mild to moderate UC; such treatment is considered most effective when combinations of both topical and oral preparations are used \[[@CR8], [@CR9]\]. Corticosteroids may be indicated in patients in whom 5-ASA formulations are ineffective in inducing remission \[[@CR8], [@CR9]\]. However, first-generation corticosteroids, such as prednisone, are associated with a number of potential safety concerns, including increased risks of serious infections, bone disease, the development of cushingoid features, and increased risk of mortality \[[@CR8], [@CR10]--[@CR12]\].

Budesonide is an orally active, second-generation corticosteroid that has affinity for the glucocorticoid receptor approximately 8.5-fold, 15-fold, and 195-fold greater than those of dexamethasone \[[@CR13]\], prednisolone \[[@CR14]\], and hydrocortisone \[[@CR14]\], respectively. A number of oral formulations are available, including oral budesonide controlled ileocolonic release (CIR) (Entocort^®^ EC, AstraZeneca LP, Wilmington, DE), budesonide capsules \[Budenofalk^®^ capsules, Dr Falk Pharma, Freiburg, Germany (not available in the USA)\], and budesonide multi-matrix (MMX^®^; Santarus, Inc.; Raleigh, NC). Budesonide CIR and budesonide capsules are not indicated for UC, but are indicated only for induction of remission of mild to moderate Crohn's disease (CD) involving the ileum and/or ascending colon; budesonide CIR is also indicated for maintenance of CD remission. However, budesonide MMX is indicated for induction of remission of mild to moderate UC. Based on data from the Colonic Release Budesonide (CORE) I and II studies \[[@CR15], [@CR16]\], which are described later in this review, an updated UC treatment algorithm has recommended budesonide MMX before the introduction of conventional corticosteroids for the induction of remission in patients for whom 5-ASA therapy has been unsuccessful, or for those who relapse during 5-ASA therapy \[[@CR10]\].

Several guidelines, developed before the availability of budesonide MMX, do not recommend oral conventional or second-generation corticosteroids for the maintenance of remission in UC \[[@CR8], [@CR9]\]; however, data are accumulating to support an acceptable tolerability profile for second-generation corticosteroids. One study, which evaluated the long-term (1-year) safety of budesonide MMX in patients with UC, indicated that oral budesonide MMX 6 mg had a safety profile similar to that of placebo \[[@CR17]\]. In addition, the CD clinical trials of budesonide CIR and budesonide capsules support the safety of oral budesonide during long-term (e.g., 1 year) exposure in patients with inflammatory bowel disease \[[@CR18]--[@CR28]\]. This article reviews the efficacy and safety profile of budesonide MMX for the treatment of UC.

Pharmacokinetic Properties of Budesonide {#Sec2}
========================================

Budesonide is a second-generation corticosteroid with low systemic bioavailability after oral administration because of extensive (\~90 %) first-pass hepatic metabolism \[[@CR29]\]. It is metabolized predominantly by hepatic cytochrome P450 3A (CYP3A) enzymes to form 2 principal metabolites: 16α-hydroxyprednisolone and 6β-hydroxybudesonide \[[@CR30]\]. These metabolites comprise only 1--10 % of the biologic activity of the parent compound \[[@CR29]\]. Following oral administration, approximately 75 % of the dose is excreted in the urine and feces \[[@CR29]\].

The MMX formulation has been designed to target orally administered drugs to sites in the distal colon \[[@CR31]\]. This delivery system utilizes an outer pH-dependent coating consisting of a hydrophilic and inert polymer matrix, which allows passage of active drug through the gastrointestinal tract to the ileum, where the outer layer of the capsule begins to dissolve at a pH \> 7.0. The active drug is therefore delivered uniformly throughout the length of the colon, thus minimizing systemic absorption, in contrast to conventional corticosteroid absorption (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR31], [@CR32]\]. MMX technology has been used effectively for the delivery of 5-ASA to the colon, whereby mesalamine MMX is being used for both induction \[[@CR31], [@CR33]--[@CR35]\] and maintenance \[[@CR36], [@CR37]\] of remission in patients with mild to moderate UC.Fig. 1Targeted delivery of budesonide MMX throughout the colon. Original art from Asklepios Medical Atlas/Science Photo Library

In pharmacokinetic studies with budesonide MMX 9 mg, the mean relative absorption of budesonide in the region between the ascending colon and the descending/sigmoid colon was 95.9 % with drug detected between 4 and \>24 h postdose (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR38]\]. This relative absorption profile contrasts with the absorption of other oral budesonide formulations: For example, following administration of budesonide CIR, approximately 69 % of the dose is absorbed in the distal ileum and ascending colon, the sites typically affected by inflammation in patients with CD \[[@CR39]\]. Release of the active drug from budesonide CIR and budesonide capsules occurs in a more acidic environment than with budesonide MMX, with absorption beginning at pH values of 5.5 and 6.4, respectively \[[@CR40], [@CR41]\].Fig. 2Scintigraphic image in a healthy volunteer showing dispersion of \[^153^Sm\]-labeled budesonide MMX in the colon. The image was obtained approximately 7 h after administration. Reprinted with permission from Brunner et al. \[[@CR38]\]

In a study of healthy volunteers, the mean lag time (*t*~lag~) between administration of budesonide MMX 9 mg and detection of budesonide in plasma was 6.8 h; the mean peak plasma concentration (*C*~max~) was 1768.7 pg/mL, and the time to *C*~max~ (*t*~max~) was 14.0 h \[[@CR38]\]. Administration of budesonide MMX with food resulted in significant decreases in both *C*~max~ (*p* = 0.03) and systemic exposure as measured by the area under the concentration--time curve to 48 h (AUC~48h~; *p* = 0.008), but these changes are not considered to be clinically meaningful \[[@CR38]\]; hence, budesonide MMX may be administered with or without food \[[@CR42]\]. After single dosing in healthy volunteers, *C*~max~, AUC~0--36 h~, AUC~0--∞~, and half-life (*t*~1/2~) of budesonide MMX 9 mg were comparable to those of budesonide CIR 9 mg \[[@CR43]\]. Median *t*~lag~ was 6 h for both 9- and 6-mg doses of budesonide MMX, compared with 1 h for budesonide CIR 9 mg \[[@CR43]\].

Because budesonide is metabolized predominantly in the liver, bioavailability may be increased in patients with impaired liver function. In a study in patients with primary biliary cirrhosis who received a single dose of budesonide 3 mg (non-MMX formulation), patients with late-stage (stage IV) disease showed significantly greater systemic exposure to budesonide than those patients with early-stage (stage I--II) disease \[[@CR44]\]. Mean *C*~max~ was 1.5 ng/mL in patients with early-stage disease, compared with 4.9 ng/mL in patients with late-stage disease (*p* \< 0.05), while mean AUC~0-∞~ values were 5.1 and 23.2 h ng/mL (*p* \< 0.01), respectively. Median *t*~1/2~ was also numerically higher in patients with late-stage disease than in those with early-stage disease (5.8 vs. 2.3 h, respectively), but this difference was not statistically significant \[[@CR44]\]. In addition, multiple dosing resulted in a significant increase in AUC~0--8 h~ at day 21 in patients with late-stage primary biliary cirrhosis compared with early-stage primary biliary cirrhosis (14.0 vs. 5.0 h ng/mL, respectively; *p* \< 0.05) \[[@CR44]\]. For this reason, patients with hepatic impairment who are receiving treatment with budesonide MMX should be monitored for symptoms of hypercorticism \[[@CR42]\].

A drawback of corticosteroid treatment is decreased drug accumulation in many patients, possibly resulting from polymorphisms in the multidrug resistance 1 (*MDR1*) gene \[[@CR45], [@CR46]\]. This phenomenon may result in the so-called glucocorticosteroid resistance and subsequent failure of patients to respond to therapy; data show that up to one-sixth of UC patients may be steroid resistant \[[@CR45], [@CR46]\]. However, in a study of healthy volunteers or patients with early-stage primary biliary cirrhosis, there were no appreciable differences in *C*~max~ or AUC and, thus, drug disposition, following administration of budesonide 3 mg (non-MMX formulation) between individuals who were homozygous for 2 common single nucleotide polymorphisms of the *MDR1* gene \[[@CR45]\].

Budesonide MMX for the Treatment of UC {#Sec3}
======================================

Budesonide MMX for the Induction of Remission of UC {#Sec4}
---------------------------------------------------

The efficacy and safety of budesonide MMX for the induction of remission in patients with mild to moderate UC \[UC disease activity index (UCDAI) score 4--10\] have been investigated in 2 identically designed, randomized trials: CORE I and II (Table [1](#Tab1){ref-type="table"}) \[[@CR15]--[@CR17], [@CR47]\]. CORE I compared budesonide MMX 9 mg and 6 mg with mesalamine 2.4 g and placebo, whereas CORE II compared the same doses of budesonide MMX with budesonide CIR 9 mg and placebo. In both studies, treatment was administered for 8 weeks, and the primary endpoint was clinical and endoscopic remission at week 8. Remission was defined as a UCDAI score ≤1, with scores of 0 for rectal bleeding and stool frequency, no mucosal friability on colonoscopy, and a reduction of ≥1 point in endoscopic index score from baseline \[[@CR15], [@CR16]\].Table 1Efficacy and safety of budesonide MMX for the treatment of ulcerative colitis remissionStudy designDisease stateTreatment and durationConcomitant and previous therapiesPrimary efficacy endpoint(s)Secondary efficacy endpointsSafety*Induction of remission*CORE I\
Sandborn et al. \[[@CR15]\]\
R, DB, DD, MC, PBO-CMild to moderate active UC (UCDAI score ≥4 and ≤10)• Budesonide MMX 9 mg qd (*n* = 123)\
• Budesonide MMX 6 mg qd (*n* = 121)\
• Mesalamine^a^ 0.8 g tid (*n* = 124)\
• PBO qd (*n* = 121) for 8 weeksNo concomitant UC therapies\
Reported previous use of any 5-ASAs:\
• Budesonide MMX 9 mg: 56.1 %\
• Budesonide MMX 6 mg: 73.6 %\
• Mesalamine 2.4 g: 63.7 %\
• PBO: 67.8 %*Clinical and endoscopic remission* ^*b*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 17.9 % (*p* = 0.014 vs. PBO)\
• Budesonide MMX 6 mg: 13.2 % (*p* = 0.14 vs. PBO)\
• Mesalamine 2.4 g: 12.1 % (*p* = 0.22 vs. PBO)\
• PBO: 7.4 %*Clinical improvement* ^*c*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 33.3 % (*p* = 0.14 vs. PBO)\
• Budesonide MMX 6 mg: 30.6 % (*p* = 0.31 vs. PBO)\
• Mesalamine 2.4 g: 33.9 % (*p* = 0.12 vs. PBO)\
• PBO: 24.8 %\
*Endoscopic improvement* ^*d*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 41.5 % (*p* = 0.17 vs. PBO)\
• Budesonide MMX 6 mg: 35.5 % (*p* = 0.68 vs. PBO)\
• Mesalamine 2.4 g: 33.1 % (*p* \> 0.99 vs. PBO)\
• PBO: 33.1 %\
*Histologic healing* ^*e*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 4.1 % (*p* = 0.38 vs. PBO)\
• Budesonide MMX 6 mg: 7.4 % (*p* = 0.80 vs. PBO)\
• Mesalamine 2.4 g: 11.3 % (*p* = 0.20 vs. PBO)\
• PBO: 6.6 %\
*Complete symptom resolution* ^*f*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 28.5 % (*p* = 0.03 vs. PBO)\
• Budesonide MMX 6 mg: 28.9 % (*p* = 0.02 vs. PBO)\
• Mesalamine 2.4 g: 25.0 % (*p* = 0.10 vs. PBO)\
• PBO: 16.5 %*Any AEs:*\
• Budesonide MMX 9 mg: 28.3 %\
• Budesonide MMX 6 mg: 27.8 %\
• Mesalamine 2.4 g: 24.4 %\
• PBO: 26.4 %\
*Potential glucocorticoid*-*related AEs* ^*g*^:\
• Budesonide MMX 9 mg: 11.8 %\
• Budesonide MMX 6 mg: 5.6 %\
• Mesalamine 2.4 g: 7.9 %\
• PBO: 10.1 %\
Mean morning plasma cortisol concentrations decreased after 2 and 4 weeks of treatment with budesonide MMX 9 mg or budesonide MMX 6 mg, but remained within normal range^h^ for all groups during studyCORE II\
Travis et al. \[[@CR16]\]\
R, DB, DD, PBO-CMild to moderate active UC (UCDAI score ≥4 and ≤10)Budesonide MMX 9 mg qd (*n* = 128)\
• Budesonide MMX 6 mg qd (*n* = 128)\
• Budesonide CIR 9 mg qd (*n* = 126)\
• PBO qd (*n* = 129) for 8 weeksNo concomitant UC therapies\
Reported previous use of any 5-ASAs:\
• Budesonide MMX 9 mg: 51.6 %\
• Budesonide MMX 6 mg: 60.2 %\
• Budesonide CIR 9 mg: 55.6 %\
• PBO: 58.1 %\
Reported previous use of sulfasalazine:\
• Budesonide MMX 9 mg: 25.8 %\
• Budesonide MMX 6 mg: 21.1 %\
• Budesonide CIR 9 mg: 23.8 %\
• PBO: 21.7 %*Clinical and endoscopic remission* ^*b*^ *rates after 8* *weeks:*\
• Budesonide MMX 9 mg: 17.4 % (*p* = 0.005 vs. PBO)\
• Budesonide MMX 6 mg: 8.3 %\
• Budesonide CIR 9 mg: 12.6 % (p = 0.048 vs. PBO)\
• PBO: 4.5 %*Clinical improvement* ^*c*^ *rates after 8* *weeks:*\
• Budesonide MMX 9 mg: 42.2 %\
• Budesonide MMX 6 mg: 25.7 %\
• Budesonide CIR 9 mg: 33.0 %\
• PBO: 33.7 %\
*Endoscopic improvement* ^*d*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 42.2 %\
• Budesonide MMX 6 mg: 25.7 %\
• Budesonide CIR 9 mg: 36.9 %\
• PBO: 31.5 %\
*Histologic healing* ^*e*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 16.5 % (*p* = 0.04 vs. PBO)\
• Budesonide MMX 6 mg: 9.2 %\
• Budesonide CIR 9 mg: 13.6 %\
• PBO: 6.7 %\
*Complete symptom resolution rates at week 8* ^*f*^:\
• Budesonide MMX 9 mg: 23.9 % (*p* = 0.02 vs. PBO)\
• Budesonide MMX 6 mg: 13.8 %\
• Budesonide CIR 9 mg: 18.4 %\
• PBO: 11.2 %*Most commonly reported AEs:*\
UC relapse:\
• Budesonide MMX 9 mg: 15.6 %\
• Budesonide MMX 6 mg: 21.1 %\
• Budesonide CIR 9 mg: 12.7 %\
• PBO: 11.6 %\
Headache:\
• Budesonide MMX 9 mg: 16.4 %\
• Budesonide MMX 6 mg: 15.6 %\
• Budesonide CIR 9 mg: 7.1 %\
• PBO: 6.2 %\
Potential glucocorticoid-related AEs^g^:\
• Budesonide MMX 9 mg: 6.3 %\
• Budesonide MMX 6 mg: 4.7 %\
• Budesonide CIR 9 mg: 11.1 %\
• PBO: 10.1 %\
Mean morning plasma cortisol concentrations within normal range^h^ after 8 weeks:\
• Budesonide MMX 9 mg: 253 nmol/L\
• Budesonide MMX 6 mg: 315 nmol/L\
• Budesonide CIR 9 mg: 323 nmol/L\
• PBO: 337 nmol/LPooled data: CORE I and CORE II\
Sandborn et al. \[[@CR47]\]\
R, DB, DD, PBO-CMild to moderate active UC (UCDAI score ≥ 4 and ≤ 10)• Budesonide MMX 9 mg qd (*n* = 232)\
• Budesonide MMX 6 mg qd (*n* = 230)\
• PBO qd (*n* = 210) for 8 weeksNo concomitant UC therapies\
Reported previous use of any 5-ASAs:\
• Budesonide MMX 9 mg: 63.4 %\
• Budesonide MMX 6 mg: 74.8 %\
• PBO: 71.0*Clinical and endoscopic remission* ^*b*^ *rates after 8* *weeks:*\
• Budesonide MMX 9 mg: 17.7 % (*p* = 0.0002 vs. PBO)\
• Budesonide MMX 6 mg: 10.9 % (*p* = 0.069 vs. PBO)\
• PBO: 6.2 %*Clinical improvement* ^*c*^ *rates after 8* *weeks:*\
• Budesonide MMX 9 mg: 37.5 % (*p* = 0.06)\
• Budesonide MMX 6 mg: 28.3 % (*p* = 0.93)\
• PBO: 28.6 %\
*Endoscopic improvement* ^*d*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 41.8 % (*p* = 0.04 vs. PBO)\
• Budesonide MMX 6 mg: 30.9 % (*p* = 0.78 vs. PBO)\
• PBO: 32.4 %\
*Histologic healing* ^*e*^ *rates at week 8:*\
• Budesonide MMX 9 mg: 9.9 % (*p* = 0.26)\
• Budesonide MMX 6 mg: 8.3 % (*p* = 0.54)\
• PBO: 6.7 %\
*Complete symptom resolution rates at week 8* ^*f*^:\
• Budesonide MMX 9 mg: 26.3 % (*p* = 0.002 vs. PBO)\
• Budesonide MMX 6 mg: 21.7 % (*p* = 0.03 vs. PBO)\
• PBO: 14.3 %*Most commonly reported AEs:*\
UC relapse:\
• Budesonide MMX 9 mg: 13.3 %\
• Budesonide MMX 6 mg: 16.5 %\
• PBO: 14.0 %\
Headache:\
• Budesonide MMX 9 mg: 11.4 %\
• Budesonide MMX 6 mg: 14.6 %\
• PBO: 10.5 %\
Potential glucocorticoid-related AEs^g^:\
• Budesonide MMX 9 mg: 9.0 %\
• Budesonide MMX 6 mg: 5.1 %\
• PBO: 10.1 %*Maintenance of remission*Sandborn et al. \[[@CR17]\]\
R, PBO-CPatients with mild to moderate UC in clinical and endoscopic remission• Budesonide MMX 6 mg qd\
• PBO qd for 12 monthsNo concomitant UC therapies without investigator approvalMaintenance of clinical remission^i^ for up to 12 months was comparable for budesonide MMX 6 mg and PBO groups*Median time to clinical relapse* ^*j*^:\
• Budesonide MMX 6 mg: \>1 year\
• PBO: 181 days (*p* = 0.02)\
*Probability of clinical relapse after 12* *months:*\
• Budesonide MMX 6 mg: 40.9 %\
• PBO: 59.7 %*Any AEs:*\
• Budesonide MMX 6 mg: 21.0 %\
• PBO: 21.3 %*5*-*ASA* 5-aminosalicylic acid, *AEs* adverse events, *CIR* controlled ileocolonic release, *CORE* Colonic Release Budesonide, *DB* double blind, *DD* double dummy, *MC* multicenter, *MMX* multi-matrix, *PBO* placebo, *PBO*-*C* placebo-controlled, *R* randomized, *UC* ulcerative colitis, *UCDAI* ulcerative colitis disease activity index^a^Asacol^®^, Proctor & Gamble Pharmaceuticals, Cincinnati, OH^b^Clinical and endoscopic remission defined as total UCDAI score ≤1, with rectal bleeding score = 0, stool frequency score = 0, no evidence of mucosal friability on colonoscopy, and decrease from baseline of ≥1 point in endoscopic index score^c^Clinical improvement defined as improvement (reduction) from baseline of ≥3 points in UCDAI score^d^Endoscopic improvement defined as decrease from baseline of ≥1 point in UCDAI endoscopy (mucosal appearance) subscore^e^Histologic healing defined as histologic score ≤1^f^Symptom resolution defined as UCDAI rectal bleeding and stool frequency subscores = 0^g^Glucocorticoid-related AEs: acne, fluid retention, flushing, hirsutism, insomnia, mood changes, moon face, sleep changes, and striae rubrae^h^Morning plasma cortisol normal range 138--690 nmol/L^i^Maintenance of remission defined as UCDAI subscores of 0 for both rectal bleeding and stool frequency^j^Time to clinical relapse defined as time to recurrence of rectal bleeding and/or stool frequency ≥1--2 stools/day more than normal for patient

In both studies, clinical and endoscopic remission was achieved in a significantly greater percentage of patients receiving budesonide MMX 9 mg compared with placebo (Table [1](#Tab1){ref-type="table"}). In CORE I, remission at week 8 was achieved in 17.9 % of patients receiving budesonide MMX 9 mg, compared with 7.4 % (*p* = 0.01) in the placebo group and 12.1 % in the group receiving mesalamine (Fig. [3](#Fig3){ref-type="fig"}a) \[[@CR15]\]. In CORE II, the 8-week remission rate was 17.4 % in patients receiving budesonide MMX 9 mg, compared with 4.5 (*p* = 0.005) and 12.6 % (*p* = 0.048) in the placebo and budesonide CIR groups, respectively (Fig. [3](#Fig3){ref-type="fig"}b) \[[@CR16]\]. In addition, a subgroup analysis in the CORE II study showed that a significantly greater percentage of patients with left-sided UC achieved clinical and endoscopic remission with budesonide MMX 9 mg than with placebo (17.7 vs. 5.8 %, respectively; *p* = 0.03); the percentage of patients with extensive disease who reached clinical and endoscopic remission was also numerically higher with budesonide MMX 9 mg than with placebo (13.8 vs. 0 %, respectively), but this difference was not statistically significant (*p* = 0.10) \[[@CR16]\].Fig. 3Combined clinical and endoscopic remission rates at week 8 in the CORE I (**a**) and CORE II (**b**) studies. Clinical and endoscopic remission was defined as a UCDAI score ≤1, with scores of 0 for rectal bleeding and stool frequency, no mucosal friability on colonoscopy, and a reduction from baseline of ≥1 point in endoscopic index score. *CI* confidence interval, *CIR* controlled ileal release. Reprinted with permission from Sandborn et al. \[[@CR15]\] and Travis et al. \[[@CR16]\]

In CORE I, an analysis by disease severity subgroup indicated that in patients with mild UC (UCDAI score 4 or 5) who received budesonide MMX 9 mg or placebo, clinical improvement (defined as a ≥3-point reduction in UCDAI score) was achieved in 44.4 and 25.0 % of patients, respectively; corresponding figures in patients with moderate disease (UCDAI score ≥6 and ≤10) were 39.7 and 30.1 %, respectively. Furthermore, the mucosal healing rate was greater with budesonide MMX 9 mg than with placebo in patients with proctosigmoiditis (32.4 vs. 19.5 %, respectively; *p* = 0.20) and left-sided UC (40.6 vs. 26.5 %, respectively; *p* = 0.22). A similar numeric difference favoring budesonide MMX 9 mg was also observed in patients with extensive UC (16.1 vs. 10.0 % with placebo), but this difference also was not statistically significant (*p* = 0.39) \[[@CR15]\].

In a pooled analysis of the CORE I and CORE II studies \[[@CR47]\], patients treated with budesonide MMX 9 mg were at least 3 times more likely to achieve clinical and endoscopic remission versus placebo \[OR 3.3 (95 % CI 1.7--6.4)\] \[[@CR47]\]. Budesonide MMX 9 mg was statistically significantly more efficacious versus placebo for several subgroups: males, females, patients ≤60 years, patients with prior mesalamine use, patients without prior mesalamine use, patients with mild UC at baseline, patients with moderate UC at baseline, patients with proctosigmoiditis, patients with left-sided UC, patients with UC duration \>1 to ≤5 years, and patients with UC duration \>5 years.

Budesonide MMX for the Maintenance of Remission of UC {#Sec5}
-----------------------------------------------------

The efficacy of budesonide MMX for the maintenance of UC remission was investigated in a study of patients who had achieved clinical and endoscopic remission in the CORE I and II studies \[[@CR15], [@CR16]\] or patients in CORE I and II who had received an additional 8 weeks of treatment (budesonide MMX 9 mg) in an open-label study (Table [1](#Tab1){ref-type="table"}) \[[@CR17], [@CR48]\]. In the maintenance study, patients were randomized to receive budesonide MMX 6 mg or placebo for up to 12 months; the primary efficacy endpoint was clinical remission, assessed after 1, 3, 6, 9, and 12 months. The median time to clinical relapse (defined as rectal bleeding, stool frequency ≥1--2 stools per day, or both) was 181 days in the placebo group, but was not reached in the budesonide MMX group (*p* = 0.02; Fig. [4](#Fig4){ref-type="fig"}) \[[@CR17]\]; at 12 months, the probability of relapse was 59.7 and 40.9 %, respectively \[[@CR17]\]. However, the percentage of patients in whom remission was maintained for up to 12 months did not differ significantly between the groups, a finding that was potentially attributable to insufficient statistical power. Therefore, the potential benefit of budesonide MMX in maintenance of remission is currently unclear and further studies are required.Fig. 4Kaplan--Meier plot showing the time to clinical relapse (defined as rectal bleeding, stool frequency ≥1--2 stools per day above normal, or both) in patients receiving maintenance therapy with budesonide MMX 6 mg or placebo for up to 1 year \[[@CR17]\]. Reprinted with permission from Sandborn et al. \[[@CR17]\]

Adverse Effects {#Sec6}
===============

In general, the budesonide molecule exhibits a more favorable safety profile than first-generation oral corticosteroids such as prednisone or prednisolone. For example, in a 10-week, double-blind, double-dummy study in 176 patients with CD who received tapering doses of prednisolone or budesonide CIR for 10 weeks, the incidence of glucocorticoid-related adverse effects was significantly lower with budesonide than with prednisolone (33 vs. 55 %, respectively; *p* = 0.003). In addition, suppression of the hypothalamic--pituitary--adrenal axis, assessed by measurement of the mean morning plasma cortisol concentration, was significantly greater with prednisolone than with budesonide CIR after 4 weeks (*p* \< 0.001) and 8 weeks (*p* = 0.02) \[[@CR49]\].

The favorable adverse event (AE) profile of budesonide MMX in UC patients was demonstrated in the CORE I and II studies \[[@CR15], [@CR16]\]. The incidence of AEs in patients receiving budesonide MMX 9 mg or 6 mg was 57.5 and 58.7 %, respectively, in CORE I, and 55.5 and 62.5 %, respectively, in CORE II. In both studies, the majority of AEs were mild or moderate in intensity, and the incidence of serious AEs was low and similar across all treatment groups. The most commonly reported AEs in patients receiving budesonide MMX were UC, headache, and nausea (Table [2](#Tab2){ref-type="table"}) \[[@CR15], [@CR16]\]. In a pooled analysis of CORE I and II, the incidence rates of predefined potential glucocorticoid-related adverse effects (acne, fluid retention, flushing, hirsutism, insomnia, mood changes, moon face, sleep changes, striae rubrae) were comparable for budesonide MMX 9 mg (10.2 %), 6 mg (7.5 %), and placebo (10.5 %) \[[@CR42]\]. The most common predefined potential glucocorticoid-related adverse effects with budesonide MMX 9 mg versus placebo were mood changes (3.5 vs. 4.3 %, respectively) and sleep changes (2.7 vs. 4.7 %, respectively) \[[@CR42]\]. In the 1-year budesonide MMX 6 mg maintenance study, the safety profile of budesonide MMX was comparable to that of placebo \[[@CR17]\].Table 2Most commonly reported adverse events (≥5 % of patients in any group) in CORE I and II studies \[[@CR15], [@CR16]\]Adverse eventStudyPatients, *n* (%)Budesonide MMX\
9 mgBudesonide MMX\
6 mgPlaceboMesalamine 2.4 gBudesonide CIR\
9 mgAny adverse eventCORE I73 (57.5)74 (58.7)81 (62.8)80 (63.0)--CORE II71 (55.5)80 (62.5)57 (44.2)--69 (54.8)UCCORE I14 (11.0)15 (11.9)21 (16.3)13 (10.2)--CORE II20 (15.6)27 (21.1)15 (11.6)--16 (12.7)HeadacheCORE I8 (6.3)17 (13.5)19 (14.7)12 (9.4)--CORE II21 (16.4)20 (15.6)8 (6.2)--9 (7.1)PyrexiaCORE I3 (2.4)5 (4.0)9 (7.0)3 (2.4)--CORE IINRNRNR--NRInsomniaCORE I5 (3.9)6 (4.8)9 (7.0)3 (2.4)--CORE IINRNRNR--NRBack painCORE I5 (3.9)4 (3.2)7 (5.4)2 (1.6)--CORE IINRNRNR--NRNauseaCORE I5 (3.9)5 (4.0)8 (6.2)10 (7.9)--CORE II8 (6.3)7 (5.5)3 (2.3)--3 (2.4)Abdominal painCORE I6 (4.7)2 (1.6)8 (6.2)10 (7.9)--CORE II3 (2.3)5 (3.9)7 (5.4)--7 (5.6)DiarrheaCORE I2 (1.6)5 (4.0)7 (5.4)8 (6.3)--CORE IINRNRNR--NRFlatulenceCORE I1 (0.8)1 (0.8)2 (1.6)7 (5.5)--CORE II5 (3.9)7 (5.5)3 (2.3)--7 (5.6)NasopharyngitisCORE INRNRNRNR--CORE II1 (0.8)8 (6.3)2 (1.6)--6 (4.8)Decreased blood cortisol levelCORE INRNRNRNR--CORE II7 (5.5)3 (2.3)1 (0.8)--4 (3.2)*CIR* controlled ileocolonic release, *CORE* Colonic Release Budesonide, *MMX* multi-matrix, *NR* not reported, *UC* ulcerative colitisAdapted with permission from Sandborn et al. \[[@CR15]\] and Travis et al. \[[@CR16]\]

Pharmacoeconomics of UC {#Sec7}
=======================

The chronic and relapsing nature of UC means that the condition imposes a substantial burden on healthcare resources, and this burden extends to society as a whole when indirect costs resulting from lost productivity are taken into account. One US study estimated that the direct medical costs of UC were \$2.7 billion \[[@CR50]\], with health insurer and patient out-of-pocket expenditures between \$390 million and \$920 million \[[@CR51]\]. Another study reported that mean estimated annual healthcare insurer expenditures were significantly greater for patients with UC than for patients without UC (\$7424 vs. \$4530, respectively, *p* \< 0.001; expenditures adjusted to 2010 US dollars) \[[@CR51]\], and that mean annual out-of-pocket costs for UC patients were \$1280 \[[@CR51]\].

Treatments that increase the likelihood of achieving and maintaining remission in UC may provide cost savings through decreased use of healthcare resources. However, the economic benefits of treatment with conventional corticosteroids in UC may be overestimated in economic models that failed to take into account the long-term adverse effects of these medications, such as the increased risk of osteoporosis and fractures \[[@CR52]\]. It remains to be determined whether the budesonide molecule, or a particular budesonide formulation, provides an economic benefit compared with conventional oral corticosteroids, although the decreased incidence of systemic adverse effects associated with budesonide may result in long-term economic benefits.

Patients with UC are often nonadherent to treatment \[[@CR53]--[@CR55]\], and this has substantial clinical and economic consequences, including increased risk of UC relapse, decreased quality of life, and increased healthcare expenditures from hospitalizations and emergency room treatments \[[@CR56], [@CR57]\]. Oral formulations of budesonide have several advantages compared with conventional oral corticosteroids, including once-daily dosing \[[@CR15], [@CR16], [@CR42], [@CR58]\], targeted absorption in the ileocolonic region or colon (depending on formulation) \[[@CR39]\], and favorable AE profiles \[[@CR15], [@CR16], [@CR28]\]. As a result, such formulations may improve patients' adherence to therapy. In a study of maintenance treatment, a greater percentage of UC patients receiving oral 5-ASA once daily were adherent to treatment after 3 and 6 months compared with patients receiving conventional twice-daily or three-times-daily dosing \[3 months: 100 vs. 70 %, respectively (*p* = 0.04); 6 months: 75 vs. 70 %, respectively (*p* = 0.8)\]. Furthermore, more patients were "very satisfied" with dosing once daily (83 %) than with dosing twice daily or three times daily (60 %), although this difference was not statistically significant \[[@CR59]\].

Conclusions {#Sec8}
===========

The budesonide MMX formulation delivers the drug throughout the colon \[[@CR31]\], in contrast to other controlled-release oral formulations of budesonide, which are targeted to the distal ileum and ascending colon---the sites primarily affected by inflammation in CD \[[@CR39]\]. Budesonide MMX has been shown to be efficacious and well tolerated for the induction of remission in patients with mild to moderate UC \[[@CR15], [@CR16]\], and the data currently available suggest that it may also be efficacious and well tolerated for maintaining long-term (up to 1 year) UC remission. The long-term safety of budesonide MMX in patients with UC was comparable to that of placebo, but these findings are limited to the single 12-month study \[[@CR17]\]. However, several studies have evaluated the use of oral formulations of budesonide as maintenance therapy in patients with CD \[[@CR18]--[@CR28]\], and these have provided support for the long-term (≥1 year) safety of budesonide for maintenance of remission of inflammatory bowel disease. Budesonide MMX may also offer pharmacoeconomic benefits by potentially increasing adherence to treatment via once-daily dosing and decreasing the risk of AEs compared with conventional oral corticosteroids. However, more work is needed in this area.
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